Bioline Pharmaceuticals

BioLineRx is a commercial-stage biopharmaceutical company focused on oncology and rare diseases, headquartered in Israel. The company's lead product, Aphexda (motixafortide), is a CXCR4 antagonist that received FDA approval in 2023 for stem cell mobilization in patients with multiple myeloma. BioLineRx is also advancing motixafortide in Phase 2 trials for pancreatic cancer and Phase 1 trials for sickle cell disease. Its pipeline includes GLIX1, a first-in-class TET2 activator targeting DNA damage response in glioblastoma, and AGI-134, a synthetic alpha-gal immunotherapy for solid tumors. The company follows a strategic model of in-licensing novel compounds and advancing them through clinical development to address significant unmet medical needs.